Weldon Mauney, MD
Neurology with Special Qualifications in Child Neurology · Gulf Breeze, FLNPI 1396915898
Payments from drug & device makers
Across 456 payments — averaging $2822.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$677K
- Amgen$224K
- Eli Lilly$72K
- H. Lundbeck A S$62K
- Zogenix Inc.$55K
- PTC Therapeutics, Inc.$44K
- plus $153K from 29 others
Across 2 payments — averaging $3585.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
- Amgen$77
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 108 | $677,312 |
| Amgen | 12 | $224,147 |
| Eli Lilly | 2 | $72,201 |
| H. Lundbeck A S | 13 | $62,442 |
| Zogenix Inc. | 9 | $54,532 |
| PTC Therapeutics, Inc. | 26 | $44,133 |
| AbbVie(2 entities) | 35 | $43,793 |
| Aquestive Therapeutics, Inc. | 11 | $38,172 |
| Neurocrine Biosciences, Inc. | 36 | $36,081 |
| Merz Pharmaceuticals, LLC | 12 | $16,576 |
| Neurelis, Inc. | 8 | $12,308 |
| UCB, Inc. | 66 | $1,492 |
| Amneal Pharmaceuticals LLC | 3 | $1,040 |
| Jazz Pharmaceuticals Inc. | 16 | $456 |
| Acadia Pharmaceuticals Inc | 11 | $278 |
| Livanova USA, Inc. | 10 | $277 |
| Eisai Inc. | 14 | $265 |
| Biogen | 11 | $239 |
| Immedica Pharma US, Inc. | 5 | $239 |
| Catalyst Pharmaceuticals, Inc. | 11 | $230 |
| Genentech USA, Inc. | 8 | $156 |
| SK Life Science, Inc. | 3 | $155 |
| Biocodex, Inc. | 5 | $135 |
| Greenwich Biosciences, Inc. | 1 | $106 |
| Saol Therapeutics Inc. | 2 | $95 |
| ITF Therapeutics LLC | 3 | $87 |
| Otter Pharmaceuticals, LLC | 2 | $70 |
| Pyros Pharmaceuticals, Inc. | 3 | $62 |
| Medtronic | 2 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Piramal Critical Care | 2 | $31 |
| Upsher-smith Laboratories LLC | 1 | $31 |
| NS Pharma, Inc. | 1 | $29 |
| Soleno Therapeutics, Inc. | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $13 |
How this compares
$1,287,281 in reported general payments places this provider in the 95th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Gulf Breeze
- James RenfroeGulf Breeze$2.9M
- Paul WinnerWest Palm Beach$18.4M
- Walter MartinezWest Palm Beach$1.9M
- Ian MillerMiami$1.1M
- Jose FerreiraTampa$876K
- Ronald DavisWinter Park$873K
- Peter KangGainesville$607K
- Omer Abdul HamidOrlando$467K
- Migvis MonduyMiami$455K
- Paula SchleiferMiami$394K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.